Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living FacilitiesMyron S. Cohen, Jason Morris, Alexander Stemer et al.|JAMA|2021Cited by 208
Clinical safety of the selective PKC-β inhibitor, ruboxistaurinJanet B. McGill, David L. Hyslop, George L. King et al.|Expert Opinion on Drug Safety|2006Cited by 48
The statistical design and analysis of pandemic platform trials: Implications for the futureChristopher J. Lindsell, Lisa M. LaVange, Matthew S. Shotwell et al.|Journal of Clinical and Translational Science|2024Cited by 2